sarcosine has been researched along with Disease Models, Animal in 46 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice." | 7.91 | The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. ( Deng, D; Ju, J; Wang, Z; Yan, R; Yao, L; Zhou, Q, 2019) |
| "Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliorate negative and cognitive symptoms of schizophrenia, including sarcosine, a glycine transporter-1 inhibitor." | 7.91 | Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. ( Hung, WL; Lai, WS; Lin, BX; Lu, LY; Luo, DZ; Min, MY; Pei, JC; Shih, MH; Studer, V; Tai, HC, 2019) |
| " The aim of this work was to evaluate the effects of brain preconditioning induced by sarcosine, a GlyT-1 inhibitor, against global cerebral ischemia and its relation to NMDAR." | 7.80 | Sarcosine preconditioning induces ischemic tolerance against global cerebral ischemia. ( da Costa, FL; de Paiva, MJ; Gomez, MV; Gomez, RS; Pinto, MC; Resende, RR; Romano-Silva, MA; Rosa, DV; Simão, F, 2014) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 7.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| " In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment." | 5.17 | Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. ( Chang, YC; Chen, KT; Huang, CC; Huang, CL; Huang, KH; Lane, HY; Tsai, GE; Tsai, MH; Tsai, P; Tun, R; Wei, IH, 2013) |
| "By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice." | 3.91 | The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. ( Deng, D; Ju, J; Wang, Z; Yan, R; Yao, L; Zhou, Q, 2019) |
| "Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliorate negative and cognitive symptoms of schizophrenia, including sarcosine, a glycine transporter-1 inhibitor." | 3.91 | Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia. ( Hung, WL; Lai, WS; Lin, BX; Lu, LY; Luo, DZ; Min, MY; Pei, JC; Shih, MH; Studer, V; Tai, HC, 2019) |
| "Sarcosine, an N-methyl-d-aspartate receptor enhancer, can improve depression-like behavior in rodent models and depression in humans." | 3.85 | Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress. ( Chen, KT; Huang, CC; Jou, MJ; Tsai, MH; Wei, IH; Wu, CH; Wu, YC, 2017) |
| " The aim of this work was to evaluate the effects of brain preconditioning induced by sarcosine, a GlyT-1 inhibitor, against global cerebral ischemia and its relation to NMDAR." | 3.80 | Sarcosine preconditioning induces ischemic tolerance against global cerebral ischemia. ( da Costa, FL; de Paiva, MJ; Gomez, MV; Gomez, RS; Pinto, MC; Resende, RR; Romano-Silva, MA; Rosa, DV; Simão, F, 2014) |
| "Effects of systemic injection of the glycine(B) agonist, d-serine, the GlyT-1 glycine transporter inhibitor, ALX-5407, and the glycine(B) antagonist, L-701,324, were tested for the effects on EtOH-induced ataxia, hypothermia, and loss of righting reflex (LORR) duration in C57BL/6J (B6) and 129S1/SvImJ (S1) inbred mice." | 3.79 | Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR glycine co-agonist site. ( Camp, M; Debrouse, L; Grant, SG; Gunduz-Cinar, O; Holmes, A; Hurd, B; Kiselycznyk, C; Mishina, M; Plitt, A; Todaro, A, 2013) |
| " The product of its enzymatic reaction-sarcosine has antipsychotic effect in patients with schizophrenia." | 3.78 | Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments. ( Chen, CJ; Chen, YM; Fan, A; Hong, CJ; Hsu, CL; Tsai, TH; Wang, HA; Yang, CP, 2012) |
| "Behavioral phenotypes relevant to schizophrenia were assessed in Grin1(D481N) mice that have reduced NMDAR glycine affinity." | 3.74 | Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. ( Labrie, V; Lipina, T; Roder, JC, 2008) |
| "Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases." | 1.72 | Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022) |
| "Sarcosine-treated DC vaccines resulted in significantly improved tumor control in a B16F10-OVA tumor flank model and improved survival in an intracranial GL261-gp100 glioma model." | 1.51 | Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling. ( Azari, H; Dastmalchi, F; Dechkovskaia, A; Karachi, A; Lovaton, RE; Mitchell, DA; Rahman, M; Saia, ME; Sayour, EJ; Vlasak, AL; Yang, C, 2019) |
| "Glycine is a strychnine-sensitive inhibitory neurotransmitter in the central nervous system (CNS), especially in the spinal cord, brainstem, and retina." | 1.43 | GlyT1 Inhibitor NFPS Exerts Neuroprotection via GlyR Alpha1 Subunit in the Rat Model of Transient Focal Cerebral Ischaemia and Reperfusion. ( Chen, G; Chen, Z; Huang, B; Li, L; Li, S; Lu, X; Qian, T; Wang, T; Xie, Q; Xu, X; Yu, W; Zhu, R, 2016) |
| "N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement." | 1.43 | N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| "The severity of tau pathology in Alzheimer's disease brain correlates closely with disease progression." | 1.40 | Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. ( Bohrmann, B; Collin, L; Göpfert, U; Grüninger, F; Oroszlan-Szovik, K; Ozmen, L, 2014) |
| "Sarcosine is a competitive inhibitor of glycine type 1 transporter." | 1.35 | Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor. ( Apkarian, AV; Centeno, MV; Millecamps, M; Mutso, A, 2009) |
| "Betaine was then intravenously administered at the same time as the methionine loading." | 1.32 | Effects of intravenous betaine on methionine-loading-induced plasma homocysteine elevation in rats. ( Nakata, R; Okawa, N; Shigematsu, N; Yagisawa, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (34.78) | 29.6817 |
| 2010's | 28 (60.87) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, C | 1 |
| Han, Y | 1 |
| Li, H | 1 |
| Yu, H | 1 |
| Zhang, B | 1 |
| Li, G | 1 |
| Liu, H | 1 |
| Liu, ZZ | 1 |
| Yao, L | 1 |
| Wang, Z | 1 |
| Deng, D | 1 |
| Yan, R | 1 |
| Ju, J | 1 |
| Zhou, Q | 1 |
| Dastmalchi, F | 1 |
| Karachi, A | 1 |
| Yang, C | 1 |
| Azari, H | 1 |
| Sayour, EJ | 1 |
| Dechkovskaia, A | 1 |
| Vlasak, AL | 1 |
| Saia, ME | 1 |
| Lovaton, RE | 1 |
| Mitchell, DA | 1 |
| Rahman, M | 1 |
| Woerman, AL | 1 |
| Kazmi, SA | 1 |
| Patel, S | 1 |
| Freyman, Y | 1 |
| Oehler, A | 1 |
| Aoyagi, A | 1 |
| Mordes, DA | 1 |
| Halliday, GM | 1 |
| Middleton, LT | 1 |
| Gentleman, SM | 1 |
| Olson, SH | 1 |
| Prusiner, SB | 1 |
| Thygesen, C | 1 |
| Metaxas, A | 1 |
| Larsen, MR | 1 |
| Finsen, B | 1 |
| Pei, JC | 1 |
| Hung, WL | 1 |
| Lin, BX | 1 |
| Shih, MH | 1 |
| Lu, LY | 1 |
| Luo, DZ | 1 |
| Tai, HC | 1 |
| Studer, V | 1 |
| Min, MY | 1 |
| Lai, WS | 1 |
| Huang, CC | 2 |
| Wei, IH | 2 |
| Huang, CL | 1 |
| Chen, KT | 2 |
| Tsai, MH | 2 |
| Tsai, P | 1 |
| Tun, R | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Lane, HY | 1 |
| Tsai, GE | 1 |
| Inami, Y | 1 |
| Sasaki, A | 1 |
| Andoh, T | 1 |
| Kuraishi, Y | 1 |
| Ando, K | 1 |
| Kabova, A | 1 |
| Stygelbout, V | 1 |
| Leroy, K | 1 |
| Heraud, C | 1 |
| Frédérick, C | 1 |
| Suain, V | 1 |
| Yilmaz, Z | 1 |
| Authelet, M | 1 |
| Dedecker, R | 1 |
| Potier, MC | 1 |
| Duyckaerts, C | 1 |
| Brion, JP | 1 |
| Chu, J | 1 |
| Lauretti, E | 1 |
| Craige, CP | 1 |
| Praticò, D | 1 |
| Pinto, MC | 2 |
| Simão, F | 1 |
| da Costa, FL | 2 |
| Rosa, DV | 2 |
| de Paiva, MJ | 1 |
| Resende, RR | 2 |
| Romano-Silva, MA | 2 |
| Gomez, MV | 2 |
| Gomez, RS | 2 |
| Collin, L | 1 |
| Bohrmann, B | 1 |
| Göpfert, U | 1 |
| Oroszlan-Szovik, K | 1 |
| Ozmen, L | 1 |
| Grüninger, F | 1 |
| Kawaura, K | 1 |
| Koike, H | 1 |
| Kinoshita, K | 1 |
| Kambe, D | 1 |
| Kaku, A | 1 |
| Karasawa, J | 1 |
| Chaki, S | 2 |
| Hikichi, H | 1 |
| Lima, IV | 1 |
| Mendes-Goulart, VA | 1 |
| de Oliveira, AC | 1 |
| de Andrade, RB | 1 |
| Gemelli, T | 1 |
| Rojas, DB | 1 |
| Dutra-Filho, CS | 1 |
| Wannmacher, CM | 1 |
| Jones, DR | 1 |
| Delenclos, M | 1 |
| Baine, AT | 1 |
| DeTure, M | 2 |
| Murray, ME | 1 |
| Dickson, DW | 2 |
| McLean, PJ | 1 |
| Kim, SY | 1 |
| Babar, N | 1 |
| Munteanu, EL | 2 |
| Takaoka, A | 2 |
| Zyablitskaya, M | 2 |
| Nagasaki, T | 2 |
| Trokel, SL | 2 |
| Paik, DC | 2 |
| Honda, M | 2 |
| Hikita, K | 1 |
| Kawamoto, B | 1 |
| Muraoka, K | 1 |
| Shimizu, S | 1 |
| Saito, M | 1 |
| Sejima, T | 1 |
| Chancellor, MB | 1 |
| Yoshimura, N | 1 |
| Takenaka, A | 1 |
| Huang, B | 1 |
| Xie, Q | 1 |
| Lu, X | 1 |
| Qian, T | 1 |
| Li, S | 1 |
| Zhu, R | 1 |
| Yu, W | 1 |
| Chen, G | 1 |
| Chen, Z | 1 |
| Xu, X | 1 |
| Wang, T | 1 |
| Li, L | 2 |
| Lin, JC | 1 |
| Chan, MH | 1 |
| Lee, MY | 1 |
| Chen, YC | 1 |
| Chen, HH | 1 |
| Wu, CH | 1 |
| Wu, YC | 1 |
| Jou, MJ | 1 |
| Heger, Z | 1 |
| Polanska, H | 1 |
| Merlos Rodrigo, MA | 1 |
| Guran, R | 1 |
| Kulich, P | 1 |
| Kopel, P | 1 |
| Masarik, M | 1 |
| Eckschlager, T | 1 |
| Stiborova, M | 1 |
| Kizek, R | 1 |
| Adam, V | 1 |
| Irimia, C | 1 |
| Buczynski, MW | 1 |
| Natividad, LA | 1 |
| Laredo, SA | 1 |
| Avalos, N | 1 |
| Parsons, LH | 1 |
| Park, KW | 1 |
| Labrie, V | 1 |
| Lipina, T | 1 |
| Roder, JC | 1 |
| Hermanns, H | 1 |
| Muth-Selbach, U | 1 |
| Williams, R | 1 |
| Krug, S | 1 |
| Lipfert, P | 1 |
| Werdehausen, R | 1 |
| Braun, S | 1 |
| Bauer, I | 1 |
| Manahan-Vaughan, D | 1 |
| Wildförster, V | 1 |
| Thomsen, C | 1 |
| Tanabe, M | 2 |
| Nakano, T | 1 |
| Ono, H | 2 |
| Centeno, MV | 1 |
| Mutso, A | 1 |
| Millecamps, M | 1 |
| Apkarian, AV | 1 |
| Ke, YD | 1 |
| Delerue, F | 1 |
| Gladbach, A | 1 |
| Götz, J | 1 |
| Ittner, LM | 1 |
| Yang, SY | 1 |
| Hong, CJ | 2 |
| Huang, YH | 1 |
| Tsai, SJ | 1 |
| Zilka, N | 1 |
| Korenova, M | 1 |
| Kovacech, B | 1 |
| Iqbal, K | 1 |
| Novak, M | 1 |
| Kodama, D | 1 |
| Yang, CP | 1 |
| Wang, HA | 1 |
| Tsai, TH | 1 |
| Fan, A | 1 |
| Hsu, CL | 1 |
| Chen, CJ | 1 |
| Chen, YM | 1 |
| Debrouse, L | 1 |
| Hurd, B | 1 |
| Kiselycznyk, C | 1 |
| Plitt, A | 1 |
| Todaro, A | 1 |
| Mishina, M | 1 |
| Grant, SG | 1 |
| Camp, M | 1 |
| Gunduz-Cinar, O | 1 |
| Holmes, A | 1 |
| Allen, B | 1 |
| Ingram, E | 1 |
| Takao, M | 1 |
| Smith, MJ | 1 |
| Jakes, R | 1 |
| Virdee, K | 1 |
| Yoshida, H | 1 |
| Holzer, M | 1 |
| Craxton, M | 1 |
| Emson, PC | 1 |
| Atzori, C | 1 |
| Migheli, A | 1 |
| Crowther, RA | 1 |
| Ghetti, B | 1 |
| Spillantini, MG | 1 |
| Goedert, M | 1 |
| Sahara, N | 2 |
| Lewis, J | 2 |
| McGowan, E | 2 |
| Hutton, M | 2 |
| Yen, SH | 2 |
| Gomeza, J | 1 |
| Hülsmann, S | 1 |
| Ohno, K | 1 |
| Eulenburg, V | 1 |
| Szöke, K | 1 |
| Richter, D | 1 |
| Betz, H | 1 |
| Vega, IE | 1 |
| Ishizawa, T | 1 |
| Dickson, D | 1 |
| Yagisawa, M | 1 |
| Okawa, N | 1 |
| Shigematsu, N | 1 |
| Nakata, R | 1 |
| Lawson, BR | 1 |
| Belkowski, SM | 1 |
| Whitesides, JF | 1 |
| Davis, P | 1 |
| Lawson, JW | 1 |
| Hashimoto, K | 1 |
| Fujita, Y | 1 |
| Ishima, T | 1 |
| Iyo, M | 1 |
| Morita, K | 1 |
| Motoyama, N | 1 |
| Kitayama, T | 1 |
| Morioka, N | 1 |
| Dohi, T | 1 |
| Mocanu, MM | 1 |
| Nissen, A | 1 |
| Eckermann, K | 1 |
| Khlistunova, I | 1 |
| Biernat, J | 1 |
| Drexler, D | 1 |
| Petrova, O | 1 |
| Schönig, K | 1 |
| Bujard, H | 1 |
| Mandelkow, E | 1 |
| Zhou, L | 1 |
| Rune, G | 1 |
| Mandelkow, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarcosine and Disease Models, Animal
| Article | Year |
|---|---|
Antinociceptive effects of glycine transporter inhibitors in neuropathic pain models in mice.
Topics: Analgesics; Animals; Brain-Derived Neurotrophic Factor; Chlorine; Disease Models, Animal; Glycine; G | 2007 |
1 trial available for sarcosine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
44 other studies available for sarcosine and Disease Models, Animal
| Article | Year |
|---|---|
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G | 2022 |
Aggressive-like behavior and increased glycine transporters in a zebrafish model of CHARGE syndrome.
Topics: Aggression; Animals; Animals, Genetically Modified; Behavior, Animal; Behavioral Symptoms; Brain; CH | 2020 |
The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model.
Topics: Animals; Cycloserine; Disease Models, Animal; Frontal Lobe; Glycine Plasma Membrane Transport Protei | 2019 |
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Topics: Adoptive Transfer; Animals; Biomarkers; Cancer Vaccines; Cell Movement; Dendritic Cells; Disease Mod | 2019 |
MSA prions exhibit remarkable stability and resistance to inactivation.
Topics: alpha-Synuclein; Animals; Biological Transport; Brain; Detergents; Disease Models, Animal; Fixatives | 2018 |
Age-Dependent Changes in the Sarkosyl-Insoluble Proteome of APPSWE/PS1ΔE9 Transgenic Mice Implicate Dysfunctional Mitochondria in the Pathogenesis of Alzheimer's Disease.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Ge | 2018 |
Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
Topics: Animals; Behavioral Symptoms; Brain Diseases; Disease Models, Animal; Dizocilpine Maleate; Excitator | 2019 |
Surfactant-induced chronic pruritus: Role of L-histidine decarboxylase expression and histamine production in epidermis.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Enzyme Induction; Epidermis; Histamine; Histamine | 2014 |
Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
Topics: Aged, 80 and over; Alzheimer Disease; Animals; Brain; Disease Models, Animal; Female; Humans; Mice; | 2014 |
Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzamides; Cell | 2014 |
Sarcosine preconditioning induces ischemic tolerance against global cerebral ischemia.
Topics: Animals; Brain Ischemia; Cell Death; Disease Models, Animal; Glycine; Glycine Plasma Membrane Transp | 2014 |
Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antibodies; Antibodies, Monoclonal; Blot | 2014 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine | 2015 |
Glycine transporters type 1 inhibitor promotes brain preconditioning against NMDA-induced excitotoxicity.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Exc | 2015 |
Chemically induced acute model of sarcosinemia in wistar rats.
Topics: Acute Disease; Amino Acid Metabolism, Inborn Errors; Animals; Animals, Newborn; Brain; Disease Model | 2016 |
Transmission of Soluble and Insoluble α-Synuclein to Mice.
Topics: Adaptation, Ocular; Age Factors; Aged; alpha-Synuclein; Animals; Brain; Calcium-Binding Proteins; De | 2015 |
Evaluating the Toxicity/Fixation Balance for Corneal Cross-Linking With Sodium Hydroxymethylglycinate (SMG) and Riboflavin-UVA (CXL) in an Ex Vivo Rabbit Model Using Confocal Laser Scanning Fluorescence Microscopy.
Topics: Animals; Calorimetry, Differential Scanning; Collagen; Cornea; Corneal Stroma; Cross-Linking Reagent | 2016 |
Spinal glycine transporter-1 inhibition influences the micturition reflex in urethane-anesthetized rats.
Topics: Anesthetics, Intravenous; Animals; Disease Models, Animal; Female; Glycine Plasma Membrane Transport | 2016 |
GlyT1 Inhibitor NFPS Exerts Neuroprotection via GlyR Alpha1 Subunit in the Rat Model of Transient Focal Cerebral Ischaemia and Reperfusion.
Topics: Animals; bcl-2-Associated X Protein; Blotting, Western; Brain; Caspase 3; Disease Models, Animal; Gl | 2016 |
N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2016 |
Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Male; MAP Kinase Signaling Syste | 2017 |
Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Evaluation of Therapeutic Tissue Crosslinking (TXL) for Myopia Using Second Harmonic Generation Signal Microscopy in Rabbit Sclera.
Topics: Animals; Collagen; Cross-Linking Reagents; Disease Models, Animal; Injections; Microscopy, Confocal; | 2017 |
Dysregulated Glycine Signaling Contributes to Increased Impulsivity during Protracted Alcohol Abstinence.
Topics: Alcohol Abstinence; Alcohol Drinking; Animals; Central Nervous System Depressants; Choice Behavior; | 2017 |
Cytoplasmic expression of mouse prion protein causes severe toxicity in Caenorhabditis elegans.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cell Movement; Cytoplasm; Detergents | 2008 |
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Carrier Proteins; Clozapine; Disease Models, Animal; Glycine; Male; Mice; | 2008 |
Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Glycine Pl | 2008 |
Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glycine; Gl | 2008 |
Glycine transporter blockade ameliorates motor ataxia in a mouse model of spinocerebellar atrophy.
Topics: Animals; Binding Sites; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Glycin | 2009 |
Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor.
Topics: Analgesics; Analysis of Variance; Animals; Cold Temperature; Disease Models, Animal; Dose-Response R | 2009 |
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Comorbidity; Diabetes Mellitus, Experimental; Disease Mod | 2009 |
The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Disease Models, Animal; Glycine Plasma Membrane Tran | 2010 |
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.
Topics: Animals; Brain; Detergents; Disease Models, Animal; Disease Progression; Humans; Longitudinal Studie | 2010 |
Increased hippocampal glycine uptake and cognitive dysfunction after peripheral nerve injury.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excitatory | 2011 |
Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments.
Topics: Animals; Antipsychotic Agents; Clozapine; Crosses, Genetic; Disease Models, Animal; Gene Expression | 2012 |
Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR glycine co-agonist site.
Topics: Alcoholic Intoxication; Animals; Ataxia; Cycloserine; Disease Models, Animal; Disks Large Homolog 4 | 2013 |
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.
Topics: Amino Acid Substitution; Animals; Apoptosis; Benzothiazoles; Brain; Brain Chemistry; Cell Count; Dis | 2002 |
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Topics: Age Factors; Amino Acid Substitution; Animals; Binding Sites; Brain; Brain Chemistry; Detergents; Di | 2002 |
Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.
Topics: Amino Acid Transport Systems, Neutral; Animals; Animals, Newborn; Brain; Disease Models, Animal; Gen | 2003 |
Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Topics: Age Factors; Alzheimer Disease; Animals; Antibodies; Antibody Specificity; Blotting, Western; Brain; | 2004 |
Effects of intravenous betaine on methionine-loading-induced plasma homocysteine elevation in rats.
Topics: Animals; Betaine; Disease Models, Animal; Glycine; Homocysteine; Hyperhomocysteinemia; Injections, I | 2004 |
Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone and Bones; Collagen; Disease Models | 2007 |
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.
Topics: Animals; Brain; Brain Chemistry; Cognition Disorders; Disease Models, Animal; Drug Administration Sc | 2008 |
The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Topics: Age Factors; Animals; Cell Death; Detergents; Disease Models, Animal; Gene Expression; Humans; Mice; | 2008 |